
Blincyto (Blinatumomab)
- « Back to Catalog
-
Blinatumomab Monoclonal antibody Type Bi-specific T-cell engager Source Mouse Target CD19, CD3 Clinical data Trade names Blincyto Synonyms AMG103, MT103 License data - EU EMA: by INN
Pregnancy
category- US: C (Risk not ruled out)
Routes of
administrationintravenous ATC code - L01XC19 (WHO)
Legal status Legal status - US: ℞-only
Pharmacokinetic data Bioavailability 100% (IV) Metabolism degradation into small peptides and amino acids Elimination half-life 2.11 hours Excretion urine (negligible) Identifiers CAS Number - 853426-35-4
DrugBank - DB09052
ChemSpider - none
UNII - 4FR53SIF3A
KEGG - D09325
Chemical and physical data Formula C2367H3577N649O772S19 Molar mass 54.1 kg/mol (what is this?) (verify)
Blinatumomab (trade name Blincyto) is a biopharmaceutical drug used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia.
-